Novonesis increases outlook for full year 2024

Novonesis increases its full-year sales and profitability outlook based on the first half year performance coupled with strong momentum going into the first months of the second half.

The 2024 outlook is increased to:

• Pro forma organic sales growth of now 7-8% (previously “upper end of 5-7%”)

• Pro forma adjusted EBITDA margin of now 35.5-36.5% (previously “35-36%”)

Additional information is made available in the Company announcement: Interim Report H1 2024.

Attachment

• 2024_26_Company_Announcement

You May Also Be Interested In

• Crypto News: AlphaPepe Announces $2.57M Raised in Presale as XRP Price Prediction Eyes $5
• Quantumsphere Acquisition Corporation Announces Termination of the Agreement and Plan of Merger with SACH Pte. Ltd.
• Two Masters, One Bottle, One Game: Charles Leclerc and Hikaru Nakamura Went Head-To-Head in a First-Of-Its-Kind Chivas Regal Showdown at Monza